Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | PRNP | P04156 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297483 | 0.96 | PTGS2 (0.50) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL2296843 | 0.92 | MAPT (0.47) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL2299408 | 0.92 | MEN1 (0.49) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL2295388 | 0.91 | MEN1 (0.49) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL2301421 | 0.91 | ALOX5 (0.57) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL6118713 | 0.90 | KDM4E (0.44) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL6119913 | 0.90 | KDM4E (0.46) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL2301053 | 0.90 | L3MBTL1 (0.40) | KDM4EALOX5MEN1KMT2AGAA | |
| SCHEMBL3537312 | 0.90 | MEN1 (0.52) | KDM4EALOX5MEN1KMT2APRNP | |
| SCHEMBL3398857 | 0.89 | PTGS2 (0.51) | KDM4EALOX5MEN1KMT2APRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567442-B | Inhibitors of hepatitis C virus polymerase | 共晶制药公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3274340-B1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA INC (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119786-B1 | 6H-FURO[2,3-E]INDOLE COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9914739-B2 | 6H-furo[2,3-E]indole compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-9914739-B2 | 6H-furo[2,3-E]indole compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-13 | — | — | US | disclosed |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2018-02-22 | — | — | US | disclosed |
| EP-2812325-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-15 | — | — | US | disclosed |
| WO-2010030592-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |
| US-7666863-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2009-11-12 | — | — | US | disclosed |
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | SAHA ASHIS K | 2007-10-04 | — | — | US | disclosed |
| US-7265152-B2 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1581207-A4 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1581207-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | VIROPHARMA INCORPORATED | 2004-08-19 | — | — | US | disclosed |
| WO-2004041201-A2 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070231318-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | KDM4E 2787/4885ALOX5 492/4885MEN1 3779/4885 |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | KDM4E 3514/4885ALOX5 2037/4885MEN1 4697/4885 |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | POLI, POLR2E, POLR2H | KDM4E 3514/4885ALOX5 2037/4885MEN1 4697/4885 |
| US-20100093694-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | KDM4E 4218/4885ALOX5 1368/4885MEN1 4676/4885 |
| US-20090281336-A1 | BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PROPHYLAXIS OF HEPATITIS C VIRAL INFECTIONS AND ASSOCIATED DISEASES | BBOX1, HAVCR2, CYP2E1 | KDM4E 2787/4885ALOX5 492/4885MEN1 3779/4885 |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | POLI, POLR2E, POLR2H | KDM4E 3514/4885ALOX5 2037/4885MEN1 4697/4885 |
| US-20040162318-A1 | Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases | BBOX1, HAVCR2, CYP2E1 | KDM4E 2787/4885ALOX5 492/4885MEN1 3779/4885 |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | KDM4E 3514/4885ALOX5 2037/4885MEN1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.